Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model

Author:

Gadkaree Shekhar K.1,Fu Juan2,Sen Rupashree2,Korrer Michael J.3,Allen Clint2,Kim Young J.3

Affiliation:

1. Department of Otolaryngology; Massachusetts Eye and Ear, Harvard Medical School; Boston MA USA

2. Department of Otolaryngology - Head and Neck Surgery; Johns Hopkins University School of Medicine; Baltimore Maryland

3. Department of Otolaryngology - Head and Neck Surgery; Vanderbilt University School of Medicine; Nashville Tennessee

Funder

National Cancer Institute

National Institutes of Health

Specialized Programs of Research Excellence (SPORE) Cancer Research

Publisher

Wiley

Subject

Otorhinolaryngology

Reference32 articles.

1. Recent advances in cancer therapy: an overview;Urruticoechea;Curr Pharm Des,2010

2. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear;Dimberu;Yale J Biol Med,2011

3. Intratumoral immunotherapy: using the tumour against itself;Crittenden;Immunology,2005

4. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

5. Synthetic biology in cell-based cancer immunotherapy;Chakravarti;Trends Biotechnol,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3